Diasorin SpA (CHIX:DIAM) Change In Receivables: €0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIAM Diasorin SpA CHIX:DIAM
78 GF Score
Price €69.54
GF Value €90.24
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Change In Receivables?

Diasorin SpA CHIX:DIAM -1.71% 78 Change In Receivables is €0 Mil as of Dec. 2025. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €90.24 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's change in receivables for the quarter that ended in Dec. 2025 was €0 Mil. It means Diasorin SpA's Accounts Receivable stayed the same from Sep. 2025 to Dec. 2025 .

Diasorin SpA's change in receivables for the fiscal year that ended in Dec. 2025 was €5 Mil. It means Diasorin SpA's Accounts Receivable declined by €5 Mil from Dec. 2024 to Dec. 2025 .

Diasorin SpA's Accounts Receivable for the quarter that ended in Dec. 2025 was €201 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Diasorin SpA's Days Sales Outstanding for the three months ended in Dec. 2025 was 62.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Diasorin SpA's liquidation value for the three months ended in Dec. 2025 was €-770 Mil.

Diasorin SpA  (CHIX:DIAm) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Diasorin SpA's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=200.702/295.055*91
=62.07

2. In Ben Graham's calculation of liquidation value, Diasorin SpA's accounts receivable are only considered to be worth 75% of book value:

Diasorin SpA's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=208.488-1296.358+0.75 * 200.702+0.5 * 334.604
=-770

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Change In Receivables Related Terms

Diasorin SpA Change In Receivables Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Change In Receivables Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.18 3.98 18.47 8.71 5.12

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:DIAM
78GF Score
Diasorin SpA CHIX:DIAM
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0 Mil mean?
Diasorin SpA (CHIX:DIAM) has a Change In Receivables of €0 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Diasorin SpA and its competitors.
Is Diasorin SpA's Change In Receivables too high?
Diasorin SpA's current Change In Receivables is €0 Mil. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Change In Receivables compare to TMO and DHR?
Diasorin SpA's Change In Receivables of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Diagnostics & Research company?
A good Change In Receivables depends on the Medical Diagnostics & Research industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Diasorin SpA and its competitors. Diasorin SpA's current Change In Receivables is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.24, compared to a current price of €69.54 — trading 22.9% below its estimated fair value. The current Change In Receivables is €0 Mil. Diasorin SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Change In Receivables is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for CHIX:DIAM:

  • Change In Receivables: €0 Mil
  • GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score

Get the complete analysis for CHIX:DIAM

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.54
Price
€90.24
GF Value